Introduction
Human embryonic stem cells (hESCs) are usually derived from the inner cell mass of blastocysts. They are characterized by unlimited growth in culture in an undifferentiated state while retaining the ability to differentiate into derivatives of the three germ layers if triggered correctly; hESCs are thus said to be pluripotent.
Future applications for these cells are legion, although the most publicized, the application in regenerative medicine is also probably the most remote in time. Positive advances so far are the differentiation into myocardial cells (Laflamme et al., 2007) and insulinproducing cells (Kroon et al., 2008) : both studies could show a positive effect of the transplantation of differentiated cells in laboratory animals.
Another more readily attainable goal would be to use these protocols to obtain differentiated cells in vitro which could be used in drug development and testing, as an alternative to animal testing (Cezar, 2007) .
During preimplantation genetic diagnosis (PGD), embryos diagnosed with a hereditary defect are obtained which are not suitable for transfer to the patient, and are thus destroyed or can be donated for research. These embryos may carry a monogenic disease (such as cystic fibrosis), an inherited chromosomal abnormality (such as an unbalanced Robertsonian or reciprocal translocation) or a clinically relevant aneuploidy such as trisomy 21. These embryos are useful for the derivation of hESC lines, and a number of reports have described the generation of some of these cell lines (Verlinsky et al., 2004 (Verlinsky et al., , 2006 Pickering et al., 2005; Mateizel et al., 2006) , but many more of these lines exist and are usually available to other research groups, but their existence is not widely known.
The hESC registry (hESCreg) was set up in April 2007 with EU funding, and was created to offer the research community, legislators, regulators and the general public at large an in-depth overview on the current status of hESC derivation and research activity in Europe (www.hescreg.eu) (Borstlap et al., 2008) . As a first step, a database was developed which is freely accessible and now contains more than 500 hESC lines that have been derived in Europe and elsewhere. Providers of hESC lines and researchers who work with these cell lines are invited to register-also free of charge-and provide detailed characteristics on their cell lines or information on their research.
Anna Veiga and Joeri Borstlap jointly co-ordinate the registry. ESHRE is also involved in the project and has a seat in the scientific advisory board.
hESCs carrying a monogenic disease present a powerful model to investigate the genetic diseases: the specific pathogenesis, pharmacogenetics and development of therapies could all be studied on these cells. Access to these lines is usually possible through material transfer agreements.
However, there is a need to broaden the access to hESC lines carrying monogenic diseases. Geneticists working on the specific monogenic diseases operate in different networks from the scientists deriving the stem cell lines, and so an effort must be made to disseminate information about the existence of these stem cell lines that could prove to be instrumental in the understanding and cure of genetic diseases. To achieve this aim, the Special Interest Groups Reproductive Genetics and Stem Cells (SIG RG and SIG SC) of ESHRE, together with the hESCreg and initiating centres, will work together to publish a yearly update in Human Reproduction, and to more widely publicize the availability of the registry, as well as the published scientific results obtained through their use.
This first review gives an overview of currently available data on stem cell lines with inherited diseases, either through publications, the internet, the registry or even personal communications, and will introduce the yearly reports to follow.
Methodology
PubMed was searched for scientific reports on stem cell lines carrying a monogenic disease. The following key words were used: 'human embryonic stem cell', 'HES(C)', 'monogenic', 'genetic' and 'chromosomal'. Lines were extracted from the hESCreg by using the following fields in the 'detailed search' window: in the 'derivation data': 'PGD' for the origin of the embryo; in the 'genetic modification': 'inherent' for the type of modification; and if the karyotype field was filled in.
Special attention was given to include only those hESC lines where it was ascertained that the origin of the genetic defect came from the embryo and was not a culture artefact. In practice, this meant that only embryos that underwent biopsy for the purpose of PGD and for the same genetic defect that was confirmed in the ensuing stem cell line could be included.
Information on the origin and characterization of the stem cell line, the genetic abnormality present, the monogenic disease carried and the availability was collected. For the characterization, information on pluripotency markers that had been tested was collected: surface markers (e.g. SSEA3 and SSEA4), expression of stemness genes (e.g. POU5F1 and NANOG), in vitro differentiation capacity in embryoid bodies and in vivo differentiation capacity to form teratoma (International Stem Cell Initiative, 2007; Stephenson et al., 2007) . Table I . A total of 56 lines with genetic abnormalities were identified, 34 from the literature, 48 from the registry (21 from the registry only), 30 from internet web sites and 34 from more than one source. Fourteen of these lines are fully characterized by the assessment of surface markers, stemness genes, in vivo and in vitro differentiation. As the database does not as yet mention the specific mutation present in the cell lines reported, most of the mutations mentioned in Table I are personal communications. All except one carry a monogenic disease; one line carries a chromosomal abnormality detected at PGS. As of 1 December 2008, hESCreg holds in total information on 527 individual hES cell lines, 215 European and 312 from elsewhere, plus information on an additional 49 lines in the UKSCB, registered as subsets to original lines. When using the PGD field in the search engine of the database, a total of 71 hES cell lines are found: only 47 of these are included in the current paper; 12 are normal lines, either because the indication for PGD was PGS and the chromosomal abnormality found in the embryo was lost in the ensuing stem cell line, or because the embryo came from a PGD cycle for HLA typing. Nine lines carried a chromosomal abnormality for which the database did not allow to check if they were embryonic in origin or culture-induced (47XX,þ16; 46XX,i(13)q(10)/46,XX; 47XY,þ5; 69,XXY; 47,XXY; 46,XXder(4;13); 47,XXþ14; 47,XXX and an unspecified translocation). One line was secondary to an original normal line, and for one line no specific mutation was given (this line was published in Verlinsky et al. (2006) as affected with Emery -Dreifuss muscular dystrophy). All of these lines are available for researchers, and for each line a source of information on how to obtain them is listed.
Results

An overview of the results is given in
The VUB03_DM1 and the VAL-6DM1 lines are used in a project to unravel the molecular mechanisms in the pathogenesis of myotonic dystrophy type 1, in collaboration with I-Stem (Institut des cellules souches pour le traitement et l'étude des maladies monogénétiques in Evry, France). The lines carrying HD (VUB05_HD and KCL008_HD2) are similarly used in a project to find biomarkers for Huntington's disease and that is funded by the EU (STEM-HD). At the VUB, those lines carrying dynamic mutations (VUB03_DM1, VUB05_HD and VUB11_FRAXA) are used as a model for the study of the behaviour of triplet expansions. The collaborative project between IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire in Strasbourg) and I-Stem is to derive hESC from embryos diagnosed at the PGD centre of Strasbourg and to send them for characterization and banking for future distribution to the scientific community by I-Stem.
However, none of these projects are currently mentioned in the registry.
Discussion
It is widely acknowledged that hESC lines carrying an inherited defect, which is most often a monogenic disease, have a great potential in the research into the pathophysiology of these diseases and for the development of therapies, either cell and gene therapy or pharmacological treatment (Ben-Yosey et al., 2008) . In order to fulfil this potential, it is paramount that knowledge of the existence of these lines becomes more widespread in the research community. A first step is easy access to information about the lines. This is precisely the primary aim of the hESCreg registry. However, we felt knowledge of the existence of the registry could be augmented through regular and easily accessible scientific literature. Moreover, the careful scrutiny carried out to compile this report revealed shortcomings in the database that are specific to genetically abnormal lines (e.g. the lack of information on the exact mutation or on the origin of the chromosomal abnormality) and that will be dealt within the coming months.
Recently, a spate of reports was published on induced pluripotent cells (iPSC). By introducing between two and four key genes by retroviral vectors, it is now possible to turn differentiated somatic cells, e.g. cells from the skin, into pluripotent cells that show many of the characteristics of hESC, although because of the introduction of the retroviruses and other factors these cells may not be completely equivalent to hESC. Nevertheless, researchers have already set up a library with 20 different iPSC lines that carry different diseases such as Huntington's disease (Park et al., 2008, www .the-scientist.com of 7 August 2008), commenting that this is the first time that these cells are available in vitro. This illustrates that the paucity of information about the existence of hESC lines that carry genetic diseases and demonstrates that this knowledge needs to be more widely disseminated.
ESHRE, and more in particular the Special Interest Groups of Reproductive Genetics and Stem Cells, can greatly help to achieve this through their large network of members, SIGs and task forces, and most of all through their journal Human Reproduction.
We have attempted to list as many of the hESC lines that carry an inherited disorder and for which information could be obtained either in the public domain-internet, scientific publications. It is highly probable that some of the lines were missed. We, therefore, call upon all the research groups that derive stem cells in Europe to join our effort and to register at the hESCreg registry.
In order to make the information more visible to research groups interested in particular genetic diseases, ESHRE's SIGs in reproductive genetics and in stem cells will annually renew this effort and publish the results in Human Reproduction.
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